CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤患者的心脏心律失常——流行病学、危险因素及新 ESC 2022 指南背景下的管理
英文原题：Cardiac Arrhythmias in Oncological Patients-Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines.
查看英文原题
Cardiac Arrhythmias in Oncological Patients-Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
综述目的：结合欧洲心脏病学会（ESC）2022 年心脏肿瘤学新指南，更新肿瘤患者心律失常的流行病学、危险因素和管理方法。近期研究进展：多种化疗药物的副作用之一是促心律失常作用。癌症本身或抗癌治疗均可诱发房性和室性心律失常。近期研究报告显示，BRAF 和 MEK 抑制剂以及 CAR-T 治疗等有前景的疗法也具有心脏毒性。肿瘤患者的心律失常危险因素与心血管疾病危险因素有重叠，但某些类别的抗癌药物会增加心脏毒性风险。临床上必须了解肿瘤治疗相关风险，并掌握发生心脏毒性时的处理方法。
展开英文摘要原文
PURPOSE OF REVIEW: To provide an update on epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients within the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology. RECENT FINDINGS: One of the side effects of different chemotherapeutics is their pro-arrhythmic activity. Both atrial and ventricular arrhythmias may be induced by cancer itself or by anticancer treatment.
Recent studies report on the cardiotoxic activity of such promising therapies as BRAF and MEK inhibitors, or CAR-T therapy. Risk factors of arrhythmias in oncological patients overlap with cardiovascular diseases risk factors, but there are some groups of anticancer drugs that increase the risk of cardiotoxicity. It is crucial to be aware of the risks associated with the oncological treatment and know how to act in case of cardiotoxicity.
论文信息
- 作者
- Gawlik M、Zimodro JM、Gąsecka A、Filipiak KJ、Szmit S
- 第一作者单位
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.Poland
- 通讯作者单位
- 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland. aleksandra.gasecka@wum.edu.pl.Poland
- 文献类型
- 综述
- 期刊
- Current oncology reports2023 Oct
- 原文标识
- PubMed 37589940 · DOI 10.1007/s11912-023-01445-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →